Home › Sakit ni Graves
Pag-aaral pangklinika para sa Sakit ni Graves na nagre-recruit sa U.S.
15 pag-aaral para sa Sakit ni Graves ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Miami, FL7 pag-aaral
- Dallas, TX7 pag-aaral
- San Antonio, TX6 pag-aaral
- Houston, TX6 pag-aaral
- Farmington Hills, MI3 pag-aaral
- Las Vegas, NV3 pag-aaral
- Torrance, CA3 pag-aaral
- San Francisco, CA3 pag-aaral
- Asheville, NC3 pag-aaral
- Akron, OH3 pag-aaral
- McKinney, TX3 pag-aaral
- Raleigh, NC3 pag-aaral
- Hialeah, FL3 pag-aaral
- El Paso, TX3 pag-aaral
- Memphis, TN3 pag-aaral
- Tucson, AZ3 pag-aaral
- Kansas City, MO3 pag-aaral
- Doral, FL3 pag-aaral
- Havelock, NC3 pag-aaral
Ayos sa estado
- Arizona5 pag-aaral
- California9 pag-aaral
- Florida8 pag-aaral
- Georgia5 pag-aaral
- Kansas4 pag-aaral
- Kentucky3 pag-aaral
- Maryland3 pag-aaral
- Michigan4 pag-aaral
- Missouri3 pag-aaral
- Nevada4 pag-aaral
- New York5 pag-aaral
- North Carolina8 pag-aaral
- Ohio4 pag-aaral
- Pennsylvania3 pag-aaral
- Tennessee4 pag-aaral
- Texas8 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT07570316Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease
Nagre-recruitPhase 3
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07661056Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 4, 2026 · NCT07682896A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Set 4, 2026 · NCT07722546A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT06727604A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT07018323NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease
Nagre-recruitPhase 1
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Ago 24, 2026 · NCT07305818Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT07753603Preoperative Corticosteroids in Autoimmune Thyroid Disease
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 5, 2026 · NCT05435547Study of BHV-1300 in Graves' Disease
Nagre-recruitPhase 1
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Hul 31, 2026 · NCT06980649Telehealth Music Therapy for Adults With Endocrine Disorder and Depression
Nagre-recruit
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Hul 30, 2026 · NCT07413874Evaluating an AI Tool for Detecting Thyrotoxic States
Nagre-recruitObservasyonal na pag-aaral
Edad 22 pataas · Lahat ng kasarian · Na-update Hun 1, 2026 · NCT07017907Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease
Nagre-recruitPhase 2
Edad 9 hanggang 17 · Lahat ng kasarian · Na-update Ene 27, 2026 · NCT07369063Personalized Treatment in Thyroid Disorders
Nagre-recruit
Edad 21 hanggang 65 · Lahat ng kasarian · Na-update Okt 15, 2025 · NCT03517579The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 23, 2024 · NCT06275373Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.